2021
Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy
Curtis SA, Raisa BM, Roberts JD, Hendrickson JE, Starrels J, Lesley D, Michelle D, Daniel Z, Brandow AM. Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy. Transfusion And Apheresis Science 2021, 61: 103304. PMID: 34782244, PMCID: PMC9838733, DOI: 10.1016/j.transci.2021.103304.Peer-Reviewed Original ResearchConceptsChronic exchange transfusionsHealth care utilizationCare utilizationExchange transfusionPain impactDisease characteristicsChronic red blood cell transfusionsRed blood cell transfusionLower health care utilizationSickle Cell Disease PainExchange transfusion therapyAcute care utilizationBlood cell transfusionSimilar disease characteristicsPatient-reported outcomesLength of staySickle cell diseaseQuality of lifeCause admissionsCell transfusionNeuropathic painOpioid prescriptionsWorst painAcute painAdult patients
2020
Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome
Holkova B, Shafer D, Yazbeck V, Dave S, Bose P, Tombes MB, Shrader E, Wan W, Bandyopadhyay D, Weir C, Collins EB, Garnett A, Kmieciak M, Roberts JD, Garcia-Manero G, Grant S. Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome. Leukemia & Lymphoma 2020, 62: 1187-1194. PMID: 33356689, PMCID: PMC8106643, DOI: 10.1080/10428194.2020.1861270.Peer-Reviewed Original ResearchConceptsStable diseaseAcute leukemiaDay 1Phase 1 dose-escalation studyRefractory acute leukemiaDose-escalation studyPhase 1 studyWhole-exome sequencingComplete pathologicKaryotypic responseAdult patientsQTc prolongationFirst patientMyelodysplastic syndromeTreatment strategiesBlast crisisPatientsExceptional responseKaryotypic aberrationsBelinostatGood responseBortezomibAMLLeukemiaFurther investigationDaily Cannabis Users with Sickle Cell Disease Show Fewer Admissions than Others with Similar Pain Complaints
Curtis SA, Brandow AM, DeVeaux M, Zeltermam D, Devine L, Roberts JD. Daily Cannabis Users with Sickle Cell Disease Show Fewer Admissions than Others with Similar Pain Complaints. Cannabis And Cannabinoid Research 2020, 5: 255-262. PMID: 32923662, PMCID: PMC7480712, DOI: 10.1089/can.2019.0036.Peer-Reviewed Original ResearchSickle cell diseaseDaily cannabis usersAnnual emergency room visitsSevere pain crisesEmergency room visitsHealth care utilizationCannabis usersCross-sectional studyPatient-reported measuresQuality of lifeSimilar disease severityHydroxyurea usePain crisisPain complaintsHospital admissionCare utilizationRoom visitsPain impactSeverity scoreDisease showAnnual admissionsCell diseaseER useDaily cannabisDisease severityMedical marijuana certification for patients with sickle cell disease: a report of a single center experience
Curtis SA, Lew D, Spodick J, Hendrickson JE, Minniti CP, Roberts JD. Medical marijuana certification for patients with sickle cell disease: a report of a single center experience. Blood Advances 2020, 4: 3814-3821. PMID: 32790846, PMCID: PMC7448584, DOI: 10.1182/bloodadvances.2020002325.Peer-Reviewed Original ResearchConceptsOpioid useMedical marijuanaSickle cell disease (SCD) reportBaseline opioid useSingle-center experienceHealth care utilizationSickle cell diseaseOpioid utilizationClinical characteristicsMost patientsCenter experienceCare utilizationSCD patientsInpatient hospitalizationRandom patientsAdmission ratesCell diseasePatientsRetrospective dataDisease reportsStudy periodHealth careCannabis productsCannabisEdible cannabis productsUrinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use
Koch CD, Xu L, Curtis SA, Roberts JD, Bunch DR, El-Khoury JM. Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use. Clinica Chimica Acta 2020, 510: 515-521. PMID: 32795544, DOI: 10.1016/j.cca.2020.08.014.Peer-Reviewed Original ResearchConceptsCannabis useUrine samplesLoss of appetiteMinor cannabinoidsRapid LC-MS/MSDronabinol groupDronabinol therapyDronabinol useSevere nauseaPain managementPositive subjectsNormal controlsTherapeutic potentialProspective sampleClinical urine samplesCancer chemotherapySpecific populationsCannabisCannabinoidsMetabolite concentrationsDronabinolLC-MS/MSNegative controlDetection of cannabisCannabidiolBuilding access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects
Kanter J, Smith WR, Desai PC, Treadwell M, Andemariam B, Little J, Nugent D, Claster S, Manwani DG, Baker J, Strouse JJ, Osunkwo I, Stewart RW, King A, Shook LM, Roberts JD, Lanzkron S. Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Advances 2020, 4: 3804-3813. PMID: 32785684, PMCID: PMC7448595, DOI: 10.1182/bloodadvances.2020001743.Peer-Reviewed Original ResearchConceptsSickle cell diseaseSCD centerCell diseaseAdult sickle cell diseaseAcute care utilizationManagement of adultsModel of careSickle cell careHealth care professionalsHealth system levelSCD guidelinesMultisystem illnessSCD careCare utilizationEarly mortalityCenter designationClinical effectivenessClinical centersCare professionalsHematology providersMore cliniciansCare deliveryMost childrenBlood disordersCareUtilization, financial outcomes and stakeholder perspectives of a re-organized adult sickle cell program
Rousseau R, Weisberg DF, Gorero J, Parwani V, Bozzo J, Kenyon K, Smith C, Cole J, Curtis S, Forray A, Roberts JD. Utilization, financial outcomes and stakeholder perspectives of a re-organized adult sickle cell program. PLOS ONE 2020, 15: e0236360. PMID: 32706825, PMCID: PMC7380627, DOI: 10.1371/journal.pone.0236360.Peer-Reviewed Original ResearchConceptsSickle cell diseaseCell diseaseYale-New Haven HospitalAcute care servicesCare of adultsPoor socio-economic statusPersonalized care planSickle Cell ProgramNew Haven HospitalSingle nursing unitParenteral opioidsPain controlClinic visitsMost patientsPain managementChronic painOutpatient visitsPrimary complaintEmergency departmentPrimary careInpatient daysCare plansCare servicesSocio-economic statusNursing units
2019
Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain Types
Curtis S, Forray A, Hendrickson J, Roberts J. Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain Types. Blood 2019, 134: 1028. DOI: 10.1182/blood-2019-129106.Peer-Reviewed Original ResearchSickle cell diseaseNeuropathic pain qualitiesNeuropathic painNociceptive painPain impactBaseline painED usePain qualityWorse sleepOpioid usePain groupChronic painCell diseaseEpisode frequencyOutcomes Measurement Information System (PROMIS) domainsAdult Sickle Cell QualityAverage daily opioid useHigher C-reactive proteinYale-New Haven HospitalHigh ED useWorse clinical outcomesC-reactive proteinDaily opioid useEmergency department useHalf of adultsCase Management Featuring Community Health Workers Reduces Inpatient Health Care Utilization in Adults with Sickle Cell Disease
Smith W, Sop D, Johnson S, Lipato T, Ferlis M, Mcmanus C, Guy M, Hartigan S, Holt E, McHenry C, Roberts J. Case Management Featuring Community Health Workers Reduces Inpatient Health Care Utilization in Adults with Sickle Cell Disease. Blood 2019, 134: 2104. DOI: 10.1182/blood-2019-130441.Peer-Reviewed Original ResearchVirginia Commonwealth University Medical CenterCommunity health workersAdvanced practice providersSickle cell diseaseReadmission ratesInpatient daysCase managementSCD adultsOutpatient visitsCare utilizationHigh utilizersMedical homeCell diseaseHealth workersInpatient health care utilizationAdult SCD patientsED return rateAcute care utilizationHospital readmission ratesHealth care utilizationEmergency department managementNumber of patientsTotal inpatient daysPatient-provider relationshipTruven Health AnalyticsStatewide Intervention to Improve Medical Care Services Utilization Patterns of Adults Living with Sickle Cell Disease
Roberts J, Andemariam B, Bozzo J, Du C, Curtis S, Latham D, Cyr M, Magras L. Statewide Intervention to Improve Medical Care Services Utilization Patterns of Adults Living with Sickle Cell Disease. Blood 2019, 134: 517. DOI: 10.1182/blood-2019-124462.Peer-Reviewed Original ResearchSickle cell diseaseED/hospitalCommunity health networksED visitsED visit ratesEmergency departmentHospital visitsClinical team membersCell diseaseHealth NetworkHospitalization ratesHospital utilizationVisit ratesAdvisory CommitteeUtilization dataICD-9/ICDInstitutional review board approvalMedicaid programAmbulatory care servicesService utilization patternsTruven Health AnalyticsAge 16 yearsQuality improvement projectReview board approvalMann-Whitney U testInpatient pain management in sickle cell disease
Zassman SM, Zamora FJ, Roberts JD. Inpatient pain management in sickle cell disease. American Journal Of Health-System Pharmacy 2019, 76: 1965-1971. PMID: 31605120, DOI: 10.1093/ajhp/zxz228.Peer-Reviewed Original ResearchVaso-occlusive crisisSickle cell diseasePatient-controlled analgesiaOral opioidsParenteral opioidsAcute painPain controlCell diseaseAverage daily pain scoreDaily pain scoresInpatient pain managementAdequate pain controlEmergency department visitsInherited blood disorderOral regimenOpioid usagePain scoresSevere painDepartment visitsHospital admissionPain managementIncremental dosesOpioidsCommon reasonPatientsRed blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease
Balbuena‐Merle R, Curtis SA, Devine L, Gibb DR, Karafin MS, Luckey CJ, Tormey CA, Siddon AJ, Roberts JD, Hendrickson JE. Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease. Transfusion 2019, 59: 3219-3227. PMID: 31355970, PMCID: PMC7075520, DOI: 10.1111/trf.15463.Peer-Reviewed Original ResearchConceptsSickle cell diseaseMonocyte subsetsTotal monocytesCell diseaseComplications of SCDRed blood cell alloimmunizationRed blood cell alloantibodiesElectronic medical recordsTransfusion exposureSerum cytokinesIntermediate monocytesRBC alloantibodiesInflammatory milieuCD64 expressionClassical monocytesPeripheral bloodInflammatory functionsMedical recordsAntibody formationClinical significancePatientsMonocytesFlow cytometryLow expressionRespondersPrescription Opioid Misuse Index in sickle cell patients: A brief questionnaire to assess at-risk for opioid abuse.
Smith WR, McClish DK, Roberts JD, Kandalaft O, Dahman B, Knisely J, Levenson J, Roseff S, Aisiku IP. Prescription Opioid Misuse Index in sickle cell patients: A brief questionnaire to assess at-risk for opioid abuse. Journal Of Opioid Management 2019, 15: 323-331. PMID: 31637684, DOI: 10.5055/jom.2019.0517.Peer-Reviewed Original ResearchConceptsOpioid misuseOpioid abuseAdult sickle cell disease patientsPrescription Opioid Misuse IndexSickle cell disease patientsAdult SCD patientsChronic opioid therapyGroup of patientsSickle cell clinicSickle cell patientsDiagnostic Interview ScheduleDSM-IV criteriaUrban teaching facilityOpioid therapySCD clinicOpioid usageAdult patientsRisk patientsSecondary outcomesHemoglobin SSPrimary outcomeSCD patientsMean ageDisease patientsProspective survey
2018
Medical Marijuana Certification for Patients with Sickle Cell Disease: A Survey Study of Patient's Use and Preferences
Curtis S, Spodick J, Lew D, Roberts J. Medical Marijuana Certification for Patients with Sickle Cell Disease: A Survey Study of Patient's Use and Preferences. Blood 2018, 132: 1094. DOI: 10.1182/blood-2018-99-118345.Peer-Reviewed Original ResearchMedical marijuanaOpioid useExact testSickle cell disease clinicMarijuana usePain medication useLess pain medicationEfficacy of marijuanaSickle cell diseaseFisher's exact testImproved safety profileMedical marijuana certificationSCD clinicPain medicationAdult patientsClinic visitsDisease clinicMedication useSymptom managementLess painSafety profileLung toxicityCell diseaseOpiate usePatientsElevated Levels of CD64 MFI on Monocyte Subsets Are Associated with a History of Stroke in Sickle Cell Disease
Curtis S, Balbuena-Merle R, Devine L, Zelterman D, Roberts J, Dearborn-Tomazos J, Sansing L, Hendrickson J. Elevated Levels of CD64 MFI on Monocyte Subsets Are Associated with a History of Stroke in Sickle Cell Disease. Blood 2018, 132: 1093. DOI: 10.1182/blood-2018-99-117504.Peer-Reviewed Original ResearchHistory of strokeSickle cell diseaseRole of monocytesIschemic strokeTotal neutrophil countComplete blood countMonocyte subsetsStroke historyNeutrophil countIntermediate monocytesMonocyte subtypesBlood countClassical monocytesCell diseaseFuture stroke riskIschemic stroke historyVaso-occlusive crisisPro-inflammatory monocytesPathophysiology of strokeCause of morbidityMultivariate logistic regressionNon-classical monocytesT-testHigh-affinity receptorStudent's t-testMedical Marijuana for Sickle Cell Disease: Results of Two Years of Certification in an Adult Sickle Cell Center
Curtis S, Lew D, Spodick J, Roberts J. Medical Marijuana for Sickle Cell Disease: Results of Two Years of Certification in an Adult Sickle Cell Center. Blood 2018, 132: 858. DOI: 10.1182/blood-2018-99-118290.Peer-Reviewed Original ResearchSickle cell diseaseAcute service utilizationOral morphine equivalentsPrevious marijuana useOpioid useDaily opioid useService utilizationHospital admissionAdmission ratesHydroxyurea useChronic painInsurance typeAcute servicesCell diseaseAcute care service utilizationTotal oral morphine equivalentsBaseline opioid useRegular clinic visitsPrescription monitoring programsMarijuana useSickle Cell CenterOnly clinical differenceQuality of lifeT-testElectronic medical recordsMarijuana Use in Adults Living with Sickle Cell Disease
Roberts JD, Spodick J, Cole J, Bozzo J, Curtis S, Forray A. Marijuana Use in Adults Living with Sickle Cell Disease. Cannabis And Cannabinoid Research 2018, 3: 162-165. PMID: 30014039, PMCID: PMC6044416, DOI: 10.1089/can.2018.0001.Peer-Reviewed Original ResearchSickle cell diseaseCell diseaseMedical marijuanaMarijuana useUrine drug testsPossible therapeutic effectsUrine drug testingAcademic medical centerTertiary careTherapeutic effectMedical CenterPatient's requestPatientsDiseaseQualifying conditionsDrug testsDrug testingCannabinoidsActive constituentsMarijuanaMedicinal indicationsPhencyclidineAdultsInstitutional recordsRecreational useA Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma
Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, Roberts JD, Sullivan D, Grant S, Holkova B. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2018, 18: 569-575.e1. PMID: 30122201, DOI: 10.1016/j.clml.2018.05.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBortezomibDrug Resistance, NeoplasmFemaleFollow-Up StudiesHumansLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisProspective StudiesSalvage TherapySurvival RateVorinostatConceptsLarge B-cell lymphomaPhase II trialStable diseaseProgressive diseaseB-cell lymphomaPartial responseII trialCohort BCohort ADay 1Median progression-free survivalNonrandomized phase II trialDiffuse large B-cell lymphomaProgression-free survivalHistone deacetylase inhibitor vorinostatOverall response rateCombination of bortezomibMantle cell lymphomaNF-κB activationProteasome inhibitor bortezomibCell lymphoma cellsPresent multicenterRefractory MCLClinical responseCohort C
2017
Predictive Ability of Intermittent Daily Sickle Cell Pain Assessment: The PiSCES Project
Smith WR, McClish DK, Levenson J, Aisiku I, Dahman B, Bovbjerg VE, Roseff S, Roberts J. Predictive Ability of Intermittent Daily Sickle Cell Pain Assessment: The PiSCES Project. Pain Medicine 2017, 19: 1972-1981. PMID: 29036363, PMCID: PMC6176749, DOI: 10.1093/pm/pnx214.Peer-Reviewed Original ResearchConceptsSickle cell diseasePain daysPain assessmentPain measuresOne weekGold standardSickle Cell Epidemiology StudyMonths strategyDaily pain assessmentProspective cohort studyOne dayPiSCES projectCohort studySCD patientsMeasurement of R2Month assessmentCell diseasePainEpidemiology studiesDiary assessmentsDaily assessmentIntermittent assessmentCrisis daysWeeksMonthsComorbidity, Pain, Utilization, and Psychosocial Outcomes in Older versus Younger Sickle Cell Adults: The PiSCES Project
McClish DK, Smith WR, Levenson JL, Aisiku IP, Roberts JD, Roseff SD, Bovbjerg VE. Comorbidity, Pain, Utilization, and Psychosocial Outcomes in Older versus Younger Sickle Cell Adults: The PiSCES Project. BioMed Research International 2017, 2017: 4070547. PMID: 28459058, PMCID: PMC5387810, DOI: 10.1155/2017/4070547.Peer-Reviewed Original ResearchConceptsSickle Cell Epidemiology StudyHealth care utilizationPain daysPiSCES projectPain frequencyAmbulatory visitsPain intensityCare utilizationPainComorbiditiesEpidemiology studiesPsychosocial measuresAge groupsAdult groupPsychosocial outcomesPsychosocial variablesOlder adultsSomatic complaintsHealth careBehavioral coping strategiesTransition groupFurther studiesPatientsAdultsSCD